Neuroendocrine prostate carcinoma (NEPC) is a rare disease that accounts for less than 1% of prostate neoplasms [1] and has an extremely poorer prognosis than the typical androgen receptor pathway-positive adenocarcinoma of the prostate (ARPC). Here, AR is linked to prostate adenocarcinoma.